Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:51 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study of CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia
NCT04209725 · SCRI Development Innovations, LLC · PHASE2 · terminated · last registry update 2023-12-05 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Closed due to slow enrollment” | – | Registry record, SCRI Development Innovations, LLC |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against POLA1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-12-03Phase 3 first posted: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS, High intensity therapies + Low intensity therapies (NCT06713837)
- 2024-10-02Phase 3 first posted: Merck Sharp & Dohme LLC, Pembrolizumab + Cisplatin (NCT06623422)
- 2024-10-01Phase 3 first posted: InnoPharmax Inc., D07001-Softgel Capsules + Placebo (NCT06622057)
- 2024-10-01Phase 3 first posted: Genmab, Rina-S + Paclitaxel (NCT06619236)
- 2024-09-26Phase 3 first posted: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, BMS-986393 + Cyclophosphamide (NCT06615479)
- 2024-09-23Phase 3 first posted: Arcus Biosciences, Inc., Quemliclustat + Placebo (NCT06608927)
- 2024-08-26Results posted on the registry: Hoffmann-La Roche, Alectnib + Cisplatin (NCT03456076)
- 2024-08-09Phase 3 first posted: Ferring Pharmaceuticals, Nadofaragene Firadenovec + Gemcitabine (NCT06545955)
- 2024-07-29Phase 3 first posted: National Cancer Institute (NCI), Carboplatin + Cisplatin (NCT06524544)
- 2024-06-21Phase 3 first posted: AstraZeneca, Gemcitabine + Cisplatin (NCT06467357)
- 2024-06-14Phase 3 first posted: Merck Sharp & Dohme LLC, Sacituzumab Tirumotecan + Pemetrexed (NCT06459180)
- 2024-03-25Phase 3 first posted: Cabaletta Bio, CABA-201 + CABA-201 (NCT06328777)
- 2024-03-20Phase 3 first posted: Janssen Research & Development, LLC, TAR-210 + Gemcitabine (NCT06319820)
- 2024-03-15Phase 3 first posted: Merck Sharp & Dohme LLC, Sacituzumab tirumotecan + Pembrolizumab (NCT06312137)
- 2024-02-28Phase 3 first posted: Jazz Pharmaceuticals, Zanidatamab + Cisplatin (NCT06282575)
- 2024-01-18Phase 3 first posted: Janssen Research & Development, LLC, TAR-200 + Mitomycin C (NCT06211764)
- 2023-12-04Phase 3 first posted: Cabaletta Bio, CABA-201 following preconditioning with fludarabine and cyclophosphamide (NCT06154252)
- 2023-11-18Phase 3 first posted: Tokyo Medical and Dental University, Systemic therapy for 12 weeks after primary registration + Same systemic therapy after secondary registration (NCT06135714)
- 2023-11-03Phase 3 first posted: Alliance for Clinical Trials in Oncology, Nab paclitaxel + Gemcitabine (NCT06115499)
- 2023-10-31Phase 3 first posted: AstraZeneca, Rilvegostomig + Placebo (NCT06109779)
- 2023-09-13Results posted on the registry: City of Hope Medical Center, Fludarabine + Itacitinib Adipate (NCT04339101)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision